A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ocrelizumab and Hyaluronidase (Ocrevus Zunovo)

Endoglycosidase class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2024-09-13
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Ocrelizumab and Hyaluronidase used for?

Ocrelizumab and Hyaluronidase is a Endoglycosidase medication tracked in Medicare Part D.

Is there a generic for Ocrelizumab and Hyaluronidase?

No. Ocrelizumab and Hyaluronidase is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ocrelizumab and Hyaluronidase?

NADAC pricing data not currently available for this drug.

Is Ocrelizumab and Hyaluronidase on the FDA shortage list?

No. Ocrelizumab and Hyaluronidase is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Endoglycosidase6 alternatives in D1
01
Amivantamab and Hyaluronidase-Lpuj (Human Recombinant)
Brand: Rybrevant Faspro
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Hyaluronidase
Brand: AMPHADASE
$53.43Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pembrolizumab and Berahyaluronidase Alfa-Pmph
Brand: KEYTRUDA QLEX
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf
Brand: Phesgo
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Rituximab and Hyaluronidase
Brand: Rituxan Hycela
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Trastuzumab and Hyaluronidase-Oysk
Brand: Herceptin Hylecta
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.